Show an ad over header. AMP

Regeneron CEO: Trump's success with antibody cocktail is not evidence of cure

Dr. Leonard Schleifer, the founder and CEO of Regeneron Pharmaceuticals, said on Sunday that President Trump's successful treatment with the company's antibody cocktail is "the weakest evidence you can get" on whether the drug produces immunity or is a cure.

Driving the news: Since leaving Walter Reed Medical Center on Monday, Trump has repeatedly claimed that he is "immune" from COVID-19 and said he views the antibody cocktail as a "cure."


What they're saying: “The president’s case is a case of one, and that’s what we call a case report. And it is evidence, but it’s kind of the weakest evidence that you can get," Schleifer told CBS News' "Face the Nation."

  • “[T]he real evidence about how good a drug is and what it will do on average has to come from these larger clinical trials, these larger randomized trials, which are the gold standard, and those are ongoing," he said.
  • The president’s case is “just low down on the evidence scale that we really need," and while the drug does create immunity, "it's probably going to last you months," Schleifer added.

The bottom line: “Regeneron can’t do this alone. We need the entire industry. And I am so proud, the industry has risen,” Schleifer said.

What to watch: Regeneron and Eli Lilly, which is developing a similar therapy, have applied for an emergency use authorization from the FDA.

Go deeper: Ex-FDA chief says Trump "definitely missed the window" to mass produce antibody drug

The dangerous instability of school re-openings

Schools across the country have flip-flopped between in-person and remote learning — and that instability is taking a toll on students' ability to learn and their mental health.

The big picture: While companies were able to set long timelines for their return, schools — under immense political and social strain — had to rush to figure out how to reopen. The cobbled-together approach has hurt students, parents and teachers alike.

Keep reading... Show less

Trump doesn't have a second-term economic plan

President Trump has not laid out an economic agenda for his second term, despite the election being just eight days away.

Why it matters: This is unprecedented in modern presidential campaigns, and makes it harder for undecided voters to make an informed choice.

Keep reading... Show less

How Trump’s energy endgame could go

Expect President Trump to redouble his efforts loosening regulations and questioning climate-change science should he win reelection next month.

Driving the news: A second Trump administration would supercharge efforts by certain states, countries and companies to address global warming. But some wildcards could have a greener tinge.

Keep reading... Show less

The swing states where the pandemic is raging

Data: The COVID Tracking Project, The Cook Political Report; Table: Andrew Witherspoon/Axios

Several states that are likely to decide which party controls Washington next year have exceptionally large coronavirus outbreaks or are seeing cases spike.

Why it matters: Most voters have already made up their minds. But for those few holdouts, the state of the pandemic could ultimately help them make a decision as they head to the polls — and that's not likely to help President Trump.

Keep reading... Show less

Tropical Storm Zeta may strengthen into hurricane before reaching U.S.

The U.S. Gulf Coast and Mexico are bracing for another possible hurricane after Tropical Storm Zeta formed in the Caribbean Sea Sunday.

Of note: Zeta is the 27th named storm of the 2020 Atlantic Hurricane season — equaling a record set in 2005.

Keep reading... Show less

Rockefeller Foundation commits $1 billion for COVID-19 recovery

The Rockefeller Foundation announced on Monday that it will allocate $1 billion over the next three years to address the pandemic and its aftermath.

Why it matters: The mishandled pandemic and the effects of climate change threaten to reverse global progress and push more than 100 million people into poverty around the world. Governments and big NGOs need to ensure that the COVID-19 recovery reaches everyone who needs it.

Keep reading... Show less

How Amy Coney Barrett will make an immediate impact on the Supreme Court

In her first week on the job,Amy Coney Barrett may be deciding which votes to count in the presidential election. By her third week, she’ll be deciding the fate of the Affordable Care Act.

Where it stands: The Senate votes on Barrett’s nomination tomorrow. If she’s confirmed, Chief Justice John Roberts is expected to swear her in at the Supreme Court within hours, an administration official tells Axios.

Keep reading... Show less

Biden team rebuffs Texas Democrats' pleas for more money

The Biden campaign is rebuffing persistent pleas from Texas Democrats to spend at least $10 million in the Lone Star state, several people familiar with the talks tell Axios.

Why it matters: If Texas — which has 38 electoral votes and is steadily getting more blue, but hasn't backed a Democrat for president since 1976 — flipped to the Biden column, it would be game over. But the RealClearPolitics polling average stubbornly hovers at +2.6 for Trump — and Team Biden appears more focused on closer targets.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories